Azathioprine Monitoring — SCE Dermatology MCQ

Correct answer: B — Non-adherence or inadequate dose — consider dose increase guided by metabolite levels

The correct answer is B, non-adherence or inadequate dose, consider dose increase guided by metabolite levels. A normal TPMT confirms the patient is a normal metaboliser, so poor response is not explained by enzyme-driven shunting. With normal TPMT and non-elevated 6-MMP but subtherapeutic 6-TGN, the active metabolite has not accumulated to an effective concentration, pointing to either missed doses or a prescribed dose too low for adequate thiopurine conversion. Since 6-TGN correlates with clinical response, the accepted approach is to use the metabolite level as a biomarker to titrate the dose (or address adherence) rather than abandon the drug class, as subtherapeutic dosing is the most common reason for thiopurine non-response. Why the other options are wrong: D. TPMT mutation: TPMT is explicitly normal here, so a variant cannot explain the pattern; TPMT deficiency would instead raise 6-TGN and marrow toxicity risk, not lower it. E. Adequate dosing, continue: disease remains uncontrolled after 8 weeks and 6-TGN is subtherapeutic, so unchanged dosing will not achieve remission; the metabolite data directly contradict adequacy. A. Drug resistance, switch immediately: true resistance is inferred only after 6-TGN has been optimised into the therapeutic range with persistent non-response; switching now abandons a correctable dosing problem prematurely. C. Laboratory error: a coherent, physiologically plausible pattern of normal TPMT, normal 6-MMP and low 6-TGN argues against assay error rather than for it, and thiopurine metabolite assays are well validated. Key point: subtherapeutic 6-TGN with normal TPMT means the dose is not achieving adequate active drug levels, so the correct action is dose titration or adherence review guided by repeat metabolite monitoring, not switching agents.

Reference: Journal of Crohn's and Colitis (Oxford Academic), Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy, 2012 (therapeutic 6-TGN threshold >=235 pmol/8x10^8 erythrocytes); principle of thiopurine metabolite-guided dosing is consistent with UK monitoring practice for azathioprine per BNF. https://academic.oup.com/ecco-jcc/article/6/6/698/382192